Hand sanitizer and surface cleaner company Byotrol had a strong 2020 and are confident about 2021 Watch Now
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Haven't seen any info on enrollments, but the trial did get moved from 'not started' to 'active' a few days ago which might indicate enrollment was progressing well:
Hopefully the new CEO will give us an update on this and the many other ongoing projects when he starts in the next week or two.
Is there any information on how many people have already received this?
This talks about first patient enrollment anticipated in July, so would have thought this should have made progress for enrolments in the last 3 months, but don't know if any info is available on enrolments.
On and UP!!! Gla :-)
SNG's market cap rose by more than £300m on encouraging Phase 2 results for Covid-19, EVG's Phase 2 results for breast cancer were outstanding and "life changing for some patients", yet EVG's market cap sits at £15m.......and of course EVG also have SFX-01 in Phase 2/3 Covid-19 patient trials...!!!???? ;-)
Undoubted UPside potential!!! Gla ;-)
Market opportunity in ER+ metastatic breast cancer
Incidence of ER+ metastatic breast cancer is approximately 130,0001 in US and Europe
CDK4/6 inhibitors are now first line treatment, in combination with hormone therapy
Pfizer (Ibrance®/palbociclib), Novartis (Kisqali®/ribociclib) and Eli Lilly (Versenio®/abemaciclib ) are the key players with billion plus sales - sales forecast to reach c.$9bn by 2021/2
All patients become resistant to CDK4/6 inhibitors
Treatment options post CDK4/6 inhibitors are generally poorly tolerated – treatments which improve quality of life are needed in this terminal population
Potential of SFX-01 to be treatment of choice post CDK4/6 inhibitor failure, extending progression free survival with favourable side-effect profile.
ah i just read! 2021!
any indications of results from the covid trial please?
Could it be the new CEO buying in 500K chunks ? He must of been shown the companies box of tricks as part of the convincer to join.
Another .5m trade at 11.30p late reported (16.54pm ), listed as a buy!!! Gla ;-)
but Who is selling at these low prices, is my question ...
2 x .5m buys earlier....the accumulation continues....Gla ;-)
We need a bit of patience here before seeing a rerate ... next month will be EVG's month , imv
Interesting line from our new mans Bio at Chronos...
“He has supervised over fifteen product launches in Europe and has completed numerous product and company acquisitions and divestments.“
and Rochester , New York. ;-)
University of Rochester Collaboration
Evgen Pharma (Evgen) and The University of Rochester School of Medicine and Dentistry have entered into a Memorandum of Understanding to advance SFX-01 towards a clinical trial in chronic kidney disease (CKD).
Thu Le, Professor of Medicine, and Chief of the Division of Nephrology at the University of Rochester Medical Center said: "We are pleased that Evgen will support our plans to undertake a clinical trial on SFX-01 in patients with CKD. Increased oxidative stress is a major molecular underpinning of CKD progression and our research suggests that patients with the GSTM1 null allele may particularly benefit from sulforaphane treatment via SFX-01 dosing."
Dr Stephen Franklin, CEO of Evgen Pharma, commented:
"We are delighted to be supporting the work of such a respected team and prestigious university. We very much hope the proposed trial will generate data demonstrating that SFX-01 could potentially improve the lives of patients suffering from CKD."
Metabolic Associate steatohepatitis (MASH)
Metabolic associated fatty liver disease (MAFLD) is now regarded as the most common liver condition in the developed world, affecting up to 30% of the general population
10%-20% of those with MAFLD have MASH and 20-30% of MASH patients are at risk of developing cirrhosis and subsequently dying from end-stage liver disease within 20 years
Professor John Dillon (University of Dundee) showed that activation of the Nrf2 pathway could reverse insulin resistance, suppress hepatic steatosis, and mitigate against MASH and liver fibrosis.
MoU with the University of Dundee to supply SFX-01 for a potential clinical trial in MASH
Option to license the clinical data to enable subsequent development/commercialisation of SFX-01 in MASH and liver fibrosis
Evgen Pharma (AIM: EVG) a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces it has entered into a Memorandum of Understanding with the The University of Dundee ("The University") to advance SFX-01 towards a clinical trial in non-alcoholic steatohepatitis ("NASH") and liver fibrosis. Evgen has agreed to supply SFX-01 to support a potential future clinical trial led by John Dillon, Professor of Hepatology and Gastrenterology in the University's School of Medicine.
With the assistance of Evgen, Professor Dillon will lead the process to secure appropriate grant funding and obtain clinical trial regulatory approval. The intention is to utilise advanced MRI scanning technology to investigate whether SFX-01 can reverse the hallmarks of NASH in a proof-of-concept clinical trial. Clinical data arising from a successful trial will support subsequent development, regulatory approval and commercialisation of SFX-01 in NASH and liver fibrosis. Evgen will be granted an option to the clinical data on fair commercial terms to enable it to advance development and commercialisation.
Non-alcoholic fatty liver disease ("NAFLD") is now regarded as the most common liver condition in the developed world, affecting up to 30% of the general population. NAFLD represents a spectrum of phenotypes ranging from simple steatosis (fatty infiltration), through NASH to cirrhosis. Approximately 30% of adults in the general population have NAFLD, and 10%-20% of these have NASH. Amongst patients with NASH, 20-30% are at risk of developing cirrhosis and subsequently dying from end-stage liver disease within 20 years. In view of the tens of thousands of individuals who are likely to develop NASH in the next decade, it is clear that this disease will represent a major burden to healthcare in the UK.
Professor John Dillon and colleagues have previously published research that showed that drug-induced activation of the Nrf2 pathway could reverse insulin resistance, suppress hepatic steatosis, and mitigated against NASH and liver fibrosis. On this basis, Professor John Dillon approached Evgen, the developer of SFX-01, a development stage drug that is known to activate the Nrf2 pathway and has demonstrated excellent safety and tolerability in previous clinical trials.
John Dillon, Professor of Hepatology and Gastrenterology at the University of Dundee's the School of Medicine said: "We are delighted that Evgen will support our plans to undertake a clinical trial on SFX-01 in patients with NASH. Oxidative stress is pivotal to the development of NASH and our research suggests that activation of the Nrf2 pathway, which in turn reduces oxidative stress, can reverse the pathology."
As well as the status of SFX-01's patient trials , more news from Unversity of Dundee also expected. Gla ;-)
Defining the Oxidative Stress-Related Mechanisms by which Activation of the Transcription Factor Nrf2 Arrests and Resolves Liver Fibrosis
Arthur, S., Dillon, J., Dinkova-Kostova, A., Hayes, J. & Henderson, C.
Medical Research Council
1/04/20 ? 31/03/24
Medical Research Council (MR/T014644/1): £2,428,412.00
mmcuch anticipated news flow has set the SP alight :(
weird one this! GL
SFX-01 Covid-19 patient trials now Active and a start date 1st August 2020!!! ;-)
A randomized controlled trial of SFX-01 to improve clinical outcomes in COVID-19 patients (STAR-COVID)
Chalmers, James (Investigator)Dinkova-Kostova, Albena (Investigator)
Molecular and Clinical MedicineCellular Medicine
Effective start/end date
1/08/20 ? 31/07/21
And a long journey to Dundee ....
Waiting at the train station but MM is one of the only passengers :-(
Potential Investigator-Led Clinical Collaborations
Guy's and St Thomas' NHS Foundation Trust
"We are working with patient groups to plan a grant application for a Phase II clinical trial programme on SFX-01 in children with ASD, hoping to recruit from a consortium of UK hospitals.
Our interest, and that of the parents of some children with ASD, was first triggered when a small clinical study showed that sulforaphane helped improve quality of life in autistic young people.
Our end goal is improving the range of treatment options available for autistic young people, in order to improve quality of life and independence.
” Dr Michael Absoud, a consultantin paediatric neurodisability"We are delighted that Evgenwill support our plans to undertake a clinical trial on SFX-01 in patients with NASH. Oxidative stress is pivotal to the development of NASH and our research suggests that activation of the Nrf2 pathway, which in turn reduces oxidative stress, can reverse the pathology.
University of Dundee
”John Dillon,Professor of Hepatology and Gastrenterology, University of Dundee's the School of Medicine "We are pleased that Evgen will support our plans to undertake a clinical trial on SFX-01 in patients with CKD.
University of Rochester- New York
Increased oxidative stress is a major molecular underpinning of CKD progression and our research suggests that patients with the GSTM1 null allele may particularly benefit from sulforaphane treatment via SFX-01 dosing.’’ Thu Le, Professor of Medicine and Chief of the Division of Nephrology at the University of Rochester Medical Center, New York.
Cheers viable, SFX-01 is in evaluation for multiple disease targets, including breast cancer in collaboration with Manchester University where phase 2 results were outstanding and life changing for some patients, and is now in the process of planned phase 2b trials. Gl ;-)
Read about my group's talented postdocs and their brilliant achievements here!
Manchester Cancer Research Centre@MCRCnews
· Sep 22
To celebrate our valued postdocs, we wanted to recognise their incredible scientific achievements over the past year that are helping to beat cancer.
Read their success in our blog here: hxxp://mcrc.manchester.ac.uk/Blog/post/postdoc-appreciation-week-mcrc-postdoc-publications
- Written by @GeorginaBinnie (1/3)
Postdoc Appreciation Week - MCRC Postdoc Publications
Postdoc Appreciation Week 2020 (21st – 25th September) is an annual event designed to highlight the global achievements and contributions of postdocs (research fellows, research associates, bioinformatic officers etc.). Originating with the National Postdoc Association in the USA (National Postdoc Appreciation Week), the University of Manchester has since won the 2019 Elsevier ‘Best New Event’ Award for Postdoc Appreciation Week and is now part of the first UK/ROI-wide consortium celebrating postdocs across UK and Irish Universities.
2019–20 peer-reviewed publications from postdocs include Dr Rachel Eyre, Dr Angélica Santiago-Gómez and Dr Bruno Simões’ co-authorship of multiple, cutting-edge articles, including:
‘Increased expression of interleukin-1 receptor characterises anti-estrogen resistant ALDH+ breast cancer stem cells’ (Santiago-Gómez, Eyre and Simões [senior author] et al.)
‘Targeting STAT3 signalling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer’ (Simões [first Author], Santiago-Gómez, Eyre et al.). Dr on the first and first author on the latter paper
‘Microenvironmental IL1ß promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling’ (Eyre [first author], Santiago-Gómez, Simões et al.)
‘PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer’ (Santiago-Gómez [first author], Simões et al)
Dr Hannah Harrison has contributed to multiple peer-reviewed papers, including as co-first author of ‘A role for CBFß in maintaining the metastatic phenotype of breast cancer cells’ and a co-author of ‘Hypoxia-induced secretion stimulates breast cancer stem cell regulatory signalling pathways’.
@ 16:14 plus many more
MM - You are obviously a dedicated follower and student of EVG. I am considering another biotech, besides continuing with SCLP, where I have been invested for 10+ years. SFX-1 looks more than just interesting. I'll give it close scrutiny.
SFX-01's Covid-19 patient trials dated to start 1/10/20.
BBC News -Scotland recorded 486 new positive coronavirus tests which represented the biggest single day's number since mass testing began.
Scottish numbers: 24 September 2020
465 new cases of COVID-19 reported; this is 7.9% of newly tested individuals.
2 new reported death(s) of people who have tested positive.
10 people were in intensive care yesterday with recently confirmed COVID-19.
84 people were in hospital with recently confirmed COVID-19.
15,362 new tests for COVID-19 that reported results.